Chronic News and Research

RSS

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Hemispherx Biopharma, Inc. will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen responsiveness at the 1st International Workshop on XMRV being held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

9 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

Columbus Regional Hospital joins Indiana Network for Patient Care

Columbus Regional Hospital is bringing the nation's largest health information exchange to the Columbus, Ind. area to better serve patients. Joining over 65 hospitals, long term care facilities and other healthcare providers, Columbus Regional Hospital is now part of a statewide network that allows physicians to securely access necessary information to make decisions critical to patient care.

8 Sep 2010

Changes in Japan's MHLW reimbursement will drive chronic dialysis catheter market

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, changes in Japan's Ministry of Health Labour and Welfare (MHLW) reimbursement, which encourage facilities to use higher-priced chronic dialysis catheters, will lead to double-digit growth in this segment over the next five years, and will support overall market revenues.

8 Sep 2010

Data finds low risk of serious complications in 2009 H1N1 infection

An analysis of data from influenza cases in Wisconsin indicates individuals with 2009 H1N1 infections were younger than those with H3N2 (2007-2008), and that the risk of most serious complications was not higher in adults or children with 2009 H1N1 compared with recent seasonal strains, according to a study in the September 8 issue of JAMA.

8 Sep 2010

KRN cell transfer model provides novel opportunity for rheumatoid arthritis research

Current research provides a novel model for rheumatoid arthritis research. The related report by LaBranche et al, "Characterization of the KRN cell transfer model of rheumatoid arthritis, a chronic yet synchronized version of the K/BxN mouse," appears in the September 2010 issue of The American Journal of Pathology.

8 Sep 2010

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma AG today announced the imminent start of the biggest ever study of an intravenous immunoglobulin preparation (IVIG) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

8 Sep 2010

Occupational exposure to substances is a major risk factor for neurodermatitis

A child who can't stop scratching himself may well be suffering from atopic dermatitis, also known as neurodermatitis. Extreme irritability of the skin with a concomitant urge to scratch is typical of the disorder. The condition often appears during the first year of life and is on the increase in industrialized countries.

8 Sep 2010

NIH expands funding for Baylor College of Medicine Human Microbiome Project

The National Institutes of Health today announced expanded funding of the Baylor College of Medicine Human Microbiome Project clinical program initiated last year at Texas Children Hospital.

8 Sep 2010

Study finds increase in emergency department usage among US patients

Only 45 percent of the 354 million annual visits for acute care in the United States are made to patients' personal physicians, as Americans increasingly make busy emergency departments, specialists or outpatient care departments their first point of contact for treatment of new health problems or a flare up of a chronic condition like asthma or diabetes.

8 Sep 2010

Study finds multivitamins have no impact on cancer recurrence, survival

Patients with colon cancer who used multivitamins during and after being treated with post-surgical chemotherapy did not reduce the risk of the cancer returning or their dying from it, according to researchers at Dana-Farber Cancer Institute.

8 Sep 2010

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.

8 Sep 2010

Researchers discover tolerance mechanism in chronic morphine treatment

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic pain, and reduce tolerance and side effects associated with morphine use. The findings are published in the July 20th issue of Science Signaling.

8 Sep 2010

St. Jude Medical to invest $60M in CardioMEMS

St. Jude Medical, Inc., a global medical device company, and privately-held CardioMEMS today announced that they have reached an agreement under which St. Jude Medical will make a $60 million equity investment in CardioMEMS, a medical device company that has developed a wireless sensing and communication technology to assess cardiac performance.

7 Sep 2010

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of the PROstate Advanced Cancer Treatment (PROACT) Phase 2 proof-of-concept clinical trial to evaluate the efficacy and safety of bafetinib in patients with advanced prostate cancer.

7 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the company received verbal notice on Friday, September 3, 2010 from the U.S. Food and Drug Administration (FDA) that the IDX184 and IDX320 programs have been placed on clinical hold.

7 Sep 2010

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostic systems and consumables for use in hospitals and commercial laboratories worldwide and provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the analysis of synovial fluid as a new product application in its Body Fluids Module utilizing its iQ®200 and iRICELL® automated microscopy analyzers.

7 Sep 2010

Combined treatment may benefit early-stage schizophrenia patients: Report

Patients with early stage schizophrenia who receive a combination of medication and a psychosocial intervention appear less likely to discontinue treatment or relapse and may have improved insight, quality of life and social functioning than those taking medication alone, according to a report in the September issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

7 Sep 2010

Childhood cancer survivors 5 times more likely to get cancer again: Study

According to a new study, children who survive cancer are at a higher risk of cancer later in life or may die early of other cause. The study included almost 900 young cancer survivors treated at Sydney Children's Hospital, from 1972 to 1999, alongside new cancer cases and early deaths. The risk of cancer was five times higher in childhood cancer survivors, the results showed, compared with the overall NSW population, that these survivors were seven and a half times more likely to die early.

5 Sep 2010

Chronic News and Research

Hemispherx Biopharma to present clinical data on XMRV retrovirus at International Workshop

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Columbus Regional Hospital joins Indiana Network for Patient Care

Changes in Japan's MHLW reimbursement will drive chronic dialysis catheter market

Data finds low risk of serious complications in 2009 H1N1 infection

KRN cell transfer model provides novel opportunity for rheumatoid arthritis research

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Occupational exposure to substances is a major risk factor for neurodermatitis

NIH expands funding for Baylor College of Medicine Human Microbiome Project

Study finds increase in emergency department usage among US patients

Study finds multivitamins have no impact on cancer recurrence, survival

NGP 555 compound effective in preventing amyloid pathology of Alzheimer's disease

Researchers discover tolerance mechanism in chronic morphine treatment

St. Jude Medical to invest $60M in CardioMEMS

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

Combined treatment may benefit early-stage schizophrenia patients: Report

Childhood cancer survivors 5 times more likely to get cancer again: Study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News